FDA rejects ecstasy treatment for PTSD
The Food and Drug Administration on Friday rejected a controversial treatment for post-traumatic stress disorder that combines ecstasy with psychotherapy. Why it matters: The decision is a major blow to psychedelic therapy advocates and investors, who pressed for the MDMA-assisted therapy to become the first psychedelic treatment approved for clinical use in the United States.FDA
The Food and Drug Administration on Friday rejected a controversial treatment for post-traumatic stress disorder that combines ecstasy with psychotherapy. Why it matters: The decision is a major blow to psychedelic therapy advocates and investors, who pressed for the MDMA-assisted therapy to become the first psychedelic treatment approved for clinical use in the United States.FDA asked Lykos to conduct an additional clinical trial on the therapy…
Read More
About Author
